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Introduction
Antiphospholipid syndrome (APS) is a disorder characterized by 
the presence of anti-phospholipid antibodies which can include Lupus 
anticoagulant and Anticardiolipin antibody [1]. These antibodies 
bind to cardiolipin and have been shown in some cases to require 
β2- glycoprotein I in order to bind to cardiolipin [2]. Symptoms of 
this disorder include vascular thrombosis without inflammation in 
the vessel wall, premature birth, spontaneous abortion, and death in a 
morphologically normal fetus at or beyond the 10th week of gestation 
[1]. APS has a strong correlation to systemic lupus erythematosus 
(SLE) with studies showing that 30% of patients with SLE will develop 
APS; however, APS can still be found in patients without SLE at a low 
frequency [3]. 
This disorder can cause cardiovascular complications 
which include marantic vegetation and valvular stenosis and/or 
regurgitation [1]. The exact mechanism of valve disease in APS is not 
fully understood, but the current belief is that there is an interaction 
between valve antigen and antiphospholipid antibodies which result 
in the observed thrombosis and valve thickening [4]. It is known 
that one third to one half of patients with APS have valve disease4 
and that APS patients with valve disease have an increased risk for 
thromboembolic events [5].
Thromboembolic events commonly found in APS include deep 
vein thrombosis, stroke, pulmonary embolism, thrombosis of renal 
vessels, and livedo reticularis [6]. Myocardial infarction is relatively 
uncommon in APS patients [6] and an APS case involving infarctions 
due to a coronary artery embolism from aortic valve thrombosis has 
not been previously published. In patients without APS, valvular 
disease is the third most common cause of coronary embolism. The 
only documented cases of coronary embolism due to aortic valve 
vegetation were caused by prosthetic heart valve complications [7].
In this study, a patient presenting with coronary artery embolic 
disease due to aortic valve thrombosis and APS is documented with 
cardiac MR (CMR).
Methods
A 20-year-old African American male with a history of migraine, 
pancreatitis and ulcerative colitis presented to the ER with acute chest 
pain, dyspnea, and vertigo. He had no history of heart attack or stroke. 
The patient underwent multiple tests including laboratory testing for 
troponin, anticardiolipin antibodies (aCL), lupus anticoagulant (LA), 
and anti-beta2-glycoprotein-1 (anti-B2GP1), blood counts, renal and 
liver function testing. He also had an EKG, cardiac catheterization, 
CMR, transthoracic echocardiography, and abdominal computed 
tomography (CT).
Results
Laboratory tests revealed elevated troponin, thrombocytopenia, 
and elevated liver function tests. Electrocardiogram revealed 
significant ST segment depression in the anterolateral leads. The patient 
was admitted and underwent cardiac catheterization which showed 
long filling defects in the large first diagonal branch (Figure 1A,B) 
and distal right coronary arteries (Figure 1C) suspicious for embolic 
disease. The patient underwent transthoracic echocardiography 
which revealed mild mitral and tricuspid regurgitation with normal 
systolic function. No cardiac mass, vegetation or thrombus was 
identified.
Multiplanar, multisequence CMR imaging of the heart was 
performed before and following the intravenous administration of 
gadolinium to evaluate myocardial viability. The cardiac MR (Figure 
2A,B,F) showed a 10 x 8 x 5 mm thrombus on the aortic valve in 
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Coronary angiography was repeated prior to surgery demonstrating 
nonocclusive disease in the left coronary artery and 80-90% stenosis 
in the distal right coronary artery.
Surgery was performed the next day to bypass the RCA stenosis 
and remove the aortic valve thrombus (Figure 2G). The right internal 
mammary artery was skeletonized and used as an in situ graft to 
the posterior descending artery and embolus was removed from 
the proximal portion of the right coronary artery. The aortic valve 
thrombus was also removed and was noted to be completely smooth 
and round with no stalk. Histopathologic examination of the aortic 
thrombus showed a fibrinous material infiltrated by histiocytes and 
neutrophils, consistent with an organizing thrombus. The patient was 
treated with heparin postoperatively and discharged with lifelong 
anti-coagulant treatment with Xarelto (rivaroxaban) 20mg orally 
once a day.
Discussion
There have been a few cases of myocardial infarction occurring 
in patients with APS published in the medical literature6. However, 
this is the first documented instance of an aortic valve thrombus 
identified on CMR in a patient with APS causing coronary artery 
embolic disease. 
This finding is extremely rare and its low frequency of reporting 
in the medical literature may be due to one of two reasons. It was 
shown in our patient that conventional angiography and TTE were 
unable to detect the aortic valve thrombus. Only CMR was able to 
detect this abnormality. It may be that aortic valve thrombosis was 
not identified in some of the previously published antiphospholipid 
patients because they are only evaluated with coronary angiography 
and TTE. The other possibility is that our case is indeed a truly rare 
complication of APS.
Conclusion
Patients with antiphospholipid syndrome are at risk for venous 
and arterial thrombosis. We report a case of a young patient presenting 
with chest pain found to have coronary embolic disease caused by 
aortic valve thrombosis related to antiphospholipid syndrome. 
Accurate diagnosis was made using a combination of conventional 
coronary angiography and cardiac MR imaging.
the noncoronary sinus. Delayed enhanced imaging displayed large 
subendocardial infarcts in the RCA, PDA, left circumflex and 
first diagonal distributions (Figure 2C-F). Multiple areas of viable 
myocardium were also demonstrated. The ventricles were mildly 
dilated and systolic function was low normal.
Blood testing was positive for anticardiolipin antibodies (aCL) 
and the patient was started on heparin therapy. The patient underwent 
computed tomography of the abdomen to evaluate his elevated 
liver function tests. Budd-Chiari Syndrome with nonocclusive 
portal vein, superior mesenteric vein, and splenic vein thrombosis 
were identified. Additionally, inferior vena cava and right external 
iliac vein thrombosis, and bilateral renal infarcts were observed. 
  Figures:  
Figure 1: (A&B) Angiogram of the left coronary artery shows string sign caused by embolus in the origin of the first diagonal branch (arrows). (C) Angiogram of the 
right coronary artery also shows multiple emboli (arrow). 
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Figure 2: (A-F) Multiplanar postcontrast CMR imaging demonstrating 
thrombus on the aortic valve (white arrows). Subendocardial infarcts are 
also seen in the anterior, septal, inferior and lateral walls (yellow arrows). (G) 
Magnification of the aortic valve thrombus (white arrow).
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